RxDoctor Payments Data

Nicole Lopez-Seminario, MD

Neurology · Roseville, CANPI 1063493567

Payments from drug & device makers

$3,896in general payments, 2019–2025

Across 249 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • EMD Serono, Inc.$362
  • SK Life Science, Inc.$288
  • AbbVie$276
  • Pfizer$206
  • Inspire Medical Systems, Inc.$189
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,894100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,896 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$150,234
Medicare patients
380
Services billed
8,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel22$27,506
Glatiramer Acetate18$25,408
Lacosamide110$20,605
VimpatLacosamide11$15,441
Aimovig AutoinjectorErenumab-Aooe12$8,584
Tegretol XrCarbamazepine13$8,029
Levetiracetam136$7,712
Lamotrigine ErLamotrigine14$7,336
Levetiracetam ErLevetiracetam66$6,588
Carbamazepine ErCarbamazepine38$4,510
Divalproex Sodium ErDivalproex Sodium30$3,775
Clobazam45$3,093
Lamotrigine139$3,006
Oxcarbazepine36$1,557
Gabapentin41$992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat$1,329$15,44111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →